NCT02947685 · OUTCOME

Duration of Response (DOR)

Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer · Source last updated 2026-02-12

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: MEDIAN
Unit: Months
Interval / dispersion: 95% Confidence Interval
Time frame: 72 months

What was measured

Defined as the time from the first documentation of objective tumor response (CR or PR) to the first documentation of objective tumor progression or to death from any cause, whichever occurs first

Analysis population: Patients that achieved confirmed response

Groups in this outcome

Arm A

Palbociclib 125 mg daily and AntiHER2 Therapy (trastuzumab/pertuzumab) q3wks + Endocrine Therapy (letrozole, anastrozole, exemstane OR fulvestratnt)

Arm B

AntiHER2 Therapy (trastuzumab/pertuzumab) q3wks + Endocrine Therapy (letrozole, anastrozole, exemstane OR fulvestrant)

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Arm A	76
Arm B	57

Reported measurements

Source class 1

Values in Months · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Arm A	44.9	Not reported	27.1	51.6	Not reported
Arm B	30.8	Not reported	26.0	NA	Upper limit not available due to low number of events

Complete source fields

classes

categories
measurements
group Id
OG000
lower Limit
27.1
upper Limit
51.6
value
44.9
comment
Upper limit not available due to low number of events
group Id
OG001
lower Limit
26.0
upper Limit
NA
value
30.8

denoms

counts
group Id
OG000
value
76
group Id
OG001
value
57
units
Participants

description

Defined as the time from the first documentation of objective tumor response (CR or PR) to the first documentation of objective tumor progression or to death from any cause, whichever occurs first

dispersion Type

95% Confidence Interval

groups

description
Palbociclib 125 mg daily and AntiHER2 Therapy (trastuzumab/pertuzumab) q3wks + Endocrine Therapy (letrozole, anastrozole, exemstane OR fulvestratnt)
id
OG000
title
Arm A
description
AntiHER2 Therapy (trastuzumab/pertuzumab) q3wks + Endocrine Therapy (letrozole, anastrozole, exemstane OR fulvestrant)
id
OG001
title
Arm B

param Type

MEDIAN

population Description

Patients that achieved confirmed response

reporting Status

POSTED

time Frame

72 months

title

Duration of Response (DOR)

type

SECONDARY

unit Of Measure

Months

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice